Unique Ingredient Identifier C151H8M554 is listed as a ingredient substance
| RN | 57-50-1 |
| EC | 200-334-9 |
| NCIT | C68477 |
| RXCUI | 10159 |
| MF | C12H22O11 |
| INCHI KEY | CZMRCDWAGMRECN-UGDNZRGBSA-N |
| SMILES | OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O |
UNII C151H8M554 SUCROSE is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| BUCCAL | TABLET | 16.6 MG |
| BUCCAL/SUBLINGUAL | TABLET | 91 MG |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 6.84 % |
| INTRAMUSCULAR | SOLUTION, INJECTION | 7.29 %W/V |
| INTRAVENOUS | INJECTION | 19.5 % |
| INTRAVENOUS | INJECTION, EMULSION | 54 MG/1ML |
| INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSP | 90 % |
| INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | 9.4 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 20 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 54 mg/vial |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 7.78 % |
| INTRAVENOUS | POWDER, FOR RECONSTITUTION | 40 % |
| INTRAVENOUS | SOLUTION, INJECTION | NA |
| INTRAVENOUS | SOLUTION, LIPOSOME, INJECTION | 8.5 % |
| IV(INFUSION) | INJECTION, LIPOSOMAL | 1 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 54 MG/1VIAL |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 5.4 % |
| ORAL | CAPSULE | 527.43 MG |
| ORAL | CAPSULE, DELAYED ACTION | 175.14 MG |
| ORAL | CAPSULE, DELAYED RELEASE | 48 MG |
| ORAL | CAPSULE, ENTERIC COATED PELLETS | 140.76 MG |
| ORAL | CAPSULE, EXTENDED RELEASE | 396.14 MG |
| ORAL | CAPSULE, HARD GELATIN | NA |
| ORAL | CAPSULE, SUSTAINED ACTION | 481.7 MG |
| ORAL | CONCENTRATE | 4250 MG/5ML |
| ORAL | DROPS | 755.5 MG/2.5ML |
| ORAL | EMULSION | NA |
| ORAL | FOR SUSPENSION | 3041 MG/5ML |
| ORAL | GRANULE | 3024.2 MG |
| ORAL | GRANULE, FOR ORAL SOLUTION | 1774.84 MG/5ML |
| ORAL | GRANULE, FOR ORAL SUSPENSION | 11 MG |
| ORAL | GRANULE, FOR RECONSTITUTION | 2669.8 MG |
| ORAL | GRANULE, FOR SUSPENSION | 2942.7 MG |
| ORAL | GRANULE, FOR SUSPENSION, EXTENDED RELEASE | NA |
| ORAL | LIQUID | 720 MG/1ML |
| ORAL | LIQUID | 250 MG/ML |
| ORAL | LIQUID | 6.25 g/10mL |
| ORAL | LIQUID,EXTENDED RELEASE | 0.8 MG/ML |
| ORAL | PASTILLE | 426 MG |
| ORAL | POWDER | 4187 MG/1PKT |
| ORAL | POWDER | 4187 MG/1SCP |
| ORAL | POWDER, FOR ORAL SOLUTION | 1933.3 MG |
| ORAL | POWDER, FOR ORAL SUSPENSION | 4636 mg |
| ORAL | POWDER, FOR ORAL SUSPENSION | 3643 MG/1PKT |
| ORAL | POWDER, FOR ORAL SUSPENSION | 3643 MG/1SCP |
| ORAL | POWDER, FOR ORAL SUSPENSION | 1195.44 MG/5ML |
| ORAL | POWDER, FOR RECONSTITUTION | 2322.79 MG/5ML |
| ORAL | POWDER, FOR SOLUTION | 1892.86 MG/2GM |
| ORAL | POWDER, FOR SUSPENSION | 9700 MG |
| ORAL | POWDER, FOR SUSPENSION | 166 MG/5ML |
| ORAL | SOLUTION | 21000 MG/30ML |
| ORAL | SOLUTION | 2000 MG/5ML |
| ORAL | SOLUTION | 30.51 %W/W |
| ORAL | SOLUTION | NA |
| ORAL | SOLUTION, ELIXIR | 2600 MG/5ML |
| ORAL | SOLUTION, SYRUP | 2255 MG/5ML |
| ORAL | SUSPENSION | 8500 MG/5ML |
| ORAL | SUSPENSION | 952.42 MG/5 ML |
| ORAL | SUSPENSION | 375 mg/1.25mL |
| ORAL | SUSPENSION | 44.44 %W/V |
| ORAL | SUSPENSION, DROPS | 1250 MG/2.5ML |
| ORAL | SUSPENSION, EXTENDED RELEASE | 1350 MG/5ML |
| ORAL | SUSPENSION, LIQUID | 1750 MG/5ML |
| ORAL | SUSPENSION, SUSTAINED ACTION | 2323.3 MG/1PKT |
| ORAL | SUSPENSION, SUSTAINED ACTION | 600 MG/5ML |
| ORAL | SUSPENSION, SYRUP, SUSTAINED ACTION | 10 % |
| ORAL | SYRUP | 85.46 % |
| ORAL | SYRUP | 2.9 g/5mL |
| ORAL | TABLET | 9700 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 2400 MG |
| ORAL | TABLET, CHEWABLE | 14.78 MG |
| ORAL | TABLET, COATED | 400 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 279.5 MG |
| ORAL | TABLET, DELAYED RELEASE | 33.5 MG |
| ORAL | TABLET, EXTENDED RELEASE | 185.07 MG |
| ORAL | TABLET, FILM COATED | 200 MG |
| ORAL | TABLET, REPEAT ACTION | 129.55 MG |
| ORAL | TABLET, SUGAR COATED | 73.18 MG |
| ORAL | TABLET, SUSTAINED ACTION | 284.54 MG |
| ORAL | TABLET, SUSTAINED ACTION, FILM COATED | 119.12 MG |
| ORAL | TABLET, UNCOATED, LOZENGE | 1255 MG |
| ORAL | TABLET, UNCOATED, TROCHE | NA |
| ORAL | WAFER | NA |
| RECTAL | LIQUID | NA |
| RECTAL | SOLUTION | 35.42 % |
| SUBCUTANEOUS | INJECTION | 17 % |
| SUBCUTANEOUS | INJECTION, SUSPENSION, EXTENDED RELEASE | 0.8 MG/0.85 ML |
| SUBCUTANEOUS | MICROCAPSULES FOR INJECTION SUSPENSION, STERILE | 0.08 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 8.21 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH | 4.1 % |
| SUBCUTANEOUS | SOLUTION, INJECTION | 7.29 % |
| SUBLINGUAL | TABLET | 17 MG |
| TOPICAL | OINTMENT | 20 %W/W |
| TRANSMUCOSAL | TABLET, UNCOATED, LOZENGE | 100.35 MG |